Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis. A new review of the data suggests that the absolute increases in these risks are fairly low, but proper care is essential to minimize them.
Other adverse effects remain, requiring careful balancing of benefits with risks
Treating prostate cancer patients with drugs that block male hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General Hospital (MGH) researchers. But the treatment does increase risks of diabetes and heart disease. How can this outcome hold true?